MLN0905 / Takeda - LARVOL DELTA

MLN0905 effectively kills gemcitabine-resistant pancreatic cancer cells by targeting PLK1. (PubMed, Eur J Med Res) - "Our research has indicated that MLN0905 interferes with cancer cell DNA replication by specifically targeting PLK1, leading to cell cycle arrest and apoptosis, thereby preventing tumor growth and effectively eradicating gemcitabine-resistant pancreatic cancer cells, demonstrating satisfactory safety in this study. This research provides a detailed analysis of the interactions between MLN0905, PLK1, and gemcitabine resistance in the progression of pancreatic cancer, offering new prospects and insights for overcoming gemcitabine resistance in pancreatic cancer."

Journal • Oncology • Pancreatic Cancer • Solid Tumor • CD31 • PECAM1 • PLK1

MLN0905, a new inhibitor of Polo-like kinase 1 (PLK1), enhances the efficiency of lenalidomide in promoting the apoptosis of multiple myeloma cell lines. (PubMed, Invest New Drugs) - "Furthermore, the combination of lenalidomide and MLN0905 synergistically decreases cell survival and induces apoptosis in AMO1 cells. The altered expression of apoptotic genes highlights the potential of this drug combination for future multiple myeloma research."

IO biomarker • Journal • Preclinical • Hematological Malignancies • Multiple Myeloma • Oncology • ANXA5 • BBC3 • BCL2 • CDKN1A • PLK1

FoxO1 is a negative regulator of neointimal hyperplasia in a rat model of patch angioplasty. (PubMed, Biomed Pharmacother) - "MLN0905 PLGA-coated patches exhibited comparable reductions in neointimal thickness and inflammatory cell accumulation. FoxO1 represents a promising therapeutic strategy for inhibiting neointimal hyperplasia."

Journal • Preclinical • FOXO1 • PCNA • PTPRC

Influence of pole-like kinase 1 on controlling contractility of the urinary tract and gene activated patterns of human bladder smooth muscle cells. (PubMed, FASEB J) - "Our findings point to a certain role of PLK-1 in of proliferation in hBSMCs and contractility in ureterovesical junction smooth muscle, which may be of relevance in lower urinary tract symptom. PLK-1 inhibitors block these effects and show shared and divergent effects. PLK-1 regulation of bladder smooth muscle growth and contraction may include genomic and nongenomic mechanisms."

Journal • Immunology • Inflammatory Arthritis • Lupus • Nephrology • Oncology • Systemic Lupus Erythematosus • Transplantation • CCL11 • KRT18 • MEN1 • PLK1 • TNFSF10